Prothena Corporation (PRTA) Osake Kurssi
Prothena Corporation Kurssi
Liikevaihto on kasvanut 8,8 % vuodessa viimeisten 16 vuoden aikana 9,68 M USD:een. Prothena Corporationn nettomarginaali on nyt −2 520,6 %, laskenut 33,4 %:sta muutama vuosi sitten. Analyytikoiden mediaanitavoitehinta on 24,50 USD, eli yli nykyhintaa 179,0 %. 12 analyytikosta 8 suosittaa ostoa — kokonaiskonsensus on Osta.
Prothena Corporation osakekurssi
Prothena Corporation liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Prothena Corporation -osakkeesta
The business model of Prothena Corporation PLC revolves around the development and commercialization of novel therapies for the treatment of progressive diseases. Prothena focuses on the discovery and development of protein immunotherapies, specifically targeting misfolded proteins that are implicated in various neurodegenerative diseases. Through its innovative approach, Prothena aims to address unmet medical needs and improve patient outcomes. By leveraging its expertise in protein engineering, it strives to create transformative therapies that have the potential to significantly impact the lives of patients. Prothena Corporation PLC is committed to advancing its pipeline and partnering with strategic collaborators to further accelerate the development and commercialization of its innovative therapies.
Prothena Corporation PLC is primarily active in the biotechnology and pharmaceutical industries.
Some of the main competitors of Prothena Corporation PLC in the market include Biogen Inc., Ionis Pharmaceuticals Inc., and Alexion Pharmaceuticals Inc.
Prothena Corporation PLC is a biotechnology company specializing in the discovery and development of novel therapies for neurodegenerative diseases. Established in 2012, Prothena originated as a spin-off from Elan Corporation, focusing primarily on antibody-based therapies. The company's research and development efforts are centered around misfolded proteins implicated in diseases like amyloidosis, Parkinson's, and Alzheimer's. With a commitment to scientific innovation, Prothena utilizes its expertise in protein engineering to create transformative treatments. By leveraging its strong pipeline and collaborations, Prothena aims to provide hope to patients suffering from debilitating disorders and improve their quality of life.
Prothena Corporation PLC has achieved several significant milestones. The company successfully generated positive results in its Phase 1 clinical trials for PRX002/RG7935, a potential treatment for Parkinson's disease. Furthermore, Prothena entered into a worldwide collaboration with Roche to develop and commercialize PRX002/RG7935, receiving an upfront payment and potential milestone payments. Additionally, Prothena advanced its pipeline with the initiation of Phase 1 clinical trials for PRX004, a potential therapy for ATTR amyloidosis. These milestones demonstrate Prothena Corporation PLC's progress in developing innovative treatments and forging key collaborations in the field of neurodegenerative diseases.
Prothena Corporation PLC is primarily present in the United States and Europe. As a multinational biotechnology company, Prothena focuses on the discovery, development, and commercialization of immunotherapies for the treatment of neurodegenerative diseases. With its headquarters in Ireland, Prothena maintains a strong presence in major cities across the United States, including South San Francisco and Cambridge. Additionally, the company has operations in several European countries, such as Switzerland and the United Kingdom. Prothena's global reach enables it to collaborate with renowned academic institutions, healthcare providers, and research organizations to advance innovative therapies for patients worldwide.
Prothena Corporation PLC is a biotechnology company that focuses on developing transformative therapies for patients with neurodegenerative diseases. The company's values revolve around scientific innovation, integrity, collaboration, and patient-centricity. Prothena is committed to advancing the understanding of disease pathways and developing novel treatments that address unmet medical needs. With a mission to improve patient outcomes, Prothena prioritizes rigorous research, strategic partnerships, and efficient development processes. By combining cutting-edge science, a strong corporate philosophy, and a dedicated team, Prothena Corporation PLC strives to bring hope and potential breakthroughs to individuals affected by debilitating neurodegenerative conditions.
Analyytikot asettavat tällä hetkellä Prothena Corporation-osakkeelle keskimääräisen tavoitehinnan 24,50 USD (mediaani: 24,50 USD), mikä merkitsee +179,0 % viimeisimpään hintaan verrattuna. Konsensus perustuu 12 analyytikkoarvioon.
12 analyytikkoa arvioi tällä hetkellä Prothena Corporation-osaketta: 8 suosittaa ostoa, 3 pitoa ja 1 myyntiä. Vuodelle 2026 analyytikot odottavat Prothena Corporation-yhtiöltä 83,16 M USD liikevaihtoa ja 0,11 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Prothena Corporation-osake noteerataan hintaan 7,74 EUR (8,78 USD).
Prothena Corporation-osake (PRTA) on listattuna 5 pörssissä, muun muassa: NASDAQ (PRTA), London (0Y3M.L), Frankfurt (0PT.F), München (0PT.MU), Düsseldorf (0PT.DU).
Prothena Corporation PLC is a leading biotechnology company specializing in the development of therapies for neurodegenerative diseases. The company, founded in 2012, is headquartered in Dublin, Ireland, and its main focus is on developing drugs against amyloid deposition in brain cells. The company's research and development division is the core of the company, where drugs targeting amyloid deposition in brain cells are developed. Prothena's production department guarantees that the drugs are produced in the highest quality and comply with strict regulatory requirements. Once a drug is approved by the FDA or EMA, Prothena markets and sells it. Prothena has developed NEOD001, a drug in clinical phase III, targeting patients with secondary systemic amyloidosis. The company also has other drugs in the pipeline focusing on Alzheimer's, Parkinson's, and ALS. Overall, Prothena is an innovative biotechnology company that makes a significant contribution to research on neurodegenerative diseases. Its focus on identifying specific antibodies against amyloid deposits in the brain is a promising approach with the potential to improve the lives of millions of people.
odotettu liikevaihto Prothena Corporation on 83,16 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Prothena Corporation on 5,92 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Prothena Corporation:n hinta-voitto-suhde (P/E) on tällä hetkellä 79,82. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Prothena Corporation-osakkeen arvostusta.
Prothena Corporation:n hinta-myynti-suhde (P/S) on tällä hetkellä 5,68. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Prothena Corporation-osakkeen arvostuskennuslukuna.
Prothena Corporation:n Eulpool-laatuscore on 2/10.
Prothena Corporation:n ISIN on IE00B91XRN20. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Prothena Corporation:n WKN on A1KAVV. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Prothena Corporation:n ticker on PRTA. Tämä pörssinoteeraus käytetään Prothena Corporation-osakkeiden kauppaan pörssissä.
Prothena Corporation osake
Prothena Corporation vertaisryhmä
Prothena Corporation Ticker
Prothena Corporation FIGI
Kaikki tunnusluvut ja syvällinen analyysi Prothena Corporation:sta
Meidän osakeanalyysimme Prothena Corporation-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Prothena Corporation:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: